ELVN
Enliven Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$49.45
−1.57%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- —
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 4.05x
- Price / sales
- —
- Price / cash flow
- -54.13x
Enterprise value
- Enterprise value
- $2.7B
- EV / sales
- —
- EV / EBITDA
- -25.80x
- EV / EBIT
- -21.94x
- Market cap
- $3.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026